GASTROINTESTINAL STROMAL TUMOR OF THE RECTUM TREATED WITH NEOADJUVANT IMATINIB FOLLOWED BY TRANSANAL

The gastrointestinal stromal tumor (GIST) is a rare type of tumor that expresses CD117 oncogene that can be detected by immunohistochemistry2. The most common sites of GISTs are stomach (70%), and small intestine (20%), while rectum is comprised in only 3% of the cases5. Although a rare condition, the GIST located in the distal rectum may require an abdominoperineal resection. There is no data to support the use of Imatinib (Gleevec from Novartis, Basel, Switzerland), a selective inhibitor of tyrosine quinase, as neoadjuvant therapy. However, the last session consensus for the treatment of GIST, suggests that this form of therapy can be used in some cases where anal sphincter is involved7. The objective of this report is to describe a case of GIST distal rectum in the rectovaginal septum with partial invasion of the anal sphincter, which was successfully treated by neoadjuvant therapy with imatinib followed by the technique of transanal endoscopic microsurgery (TEM). The results are compared with experience in the literature.

[1]  M. Morino,et al.  Transanal endoscopic microsurgery after neoadjuvant therapy for rectal GIST. , 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[2]  S. Machlenkin,et al.  The effect of neoadjuvant Imatinib therapy on outcome and survival after rectal gastrointestinal stromal tumour , 2011, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[3]  Jian-ping Wang,et al.  The Role of Neoadjuvant Imatinib Mesylate Therapy in Sphincter-Preserving Procedures for Anorectal Gastrointestinal Stromal Tumor , 2011, American journal of clinical oncology.

[4]  I. Cecconello,et al.  Transanal endoscopic microsurgery (TEM): a minimally invasive procedure for treatment of selected rectal neoplasms , 2010 .

[5]  P. Casali,et al.  Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[6]  Y. Nasu,et al.  Recurrent rectal GIST resected successfully after preoperative chemotherapy with imatinib mesylate , 2008, International Journal of Clinical Oncology.

[7]  S. Barni,et al.  Neoadjuvant imatinib in a locally advanced gastrointestinal stromal tumour (GIST) of the rectum: a rare case of two GISTs within a family without a familial GIST syndrome. , 2007, European journal of gastroenterology & hepatology.

[8]  G. Tarantino,et al.  Does a lower insulin resistance affect antiviral therapy response in patients suffering from HCV related chronic hepatitis? , 2006, Gut.

[9]  J. Blay,et al.  Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  S. Finkelstein,et al.  Neoadjuvant Imatinib in Gastrointestinal Stromal Tumor of the Rectum: Report of a Case , 2005, Diseases of the colon and rectum.